"It's very difficult to follow an individual case with a partially effective therapy because there's always the possibility that the patient would be doing worse without the treatment. So we have to make a judgement. The neutralizing antibody status will help."
--Richard A. Rudick, MD, Director of the Mellen Center for Multiple Sclerosis Treatment and Research at Cleveland Clinic Foundation. 5
Welcome to a Discussion on The
Role of Neutralizing Antibodies in Clinical
Management Decisions.
If you did not receive the previous NeuroCAST emails,
we recommend that you view Sessions I and II prior to reviewing Session III.
Begin Session III
Next
